Get the Stockscreener App
0.5086
1.23%
0.0062
Pre-market:
.53
0.0214
+4.21%
Xtant Medical Holdings Inc stock is traded at $0.5086, with a volume of 97,468.
It is up +1.23% in the last 24 hours and up +8.21% over the past month.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. The company also provides OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; and 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers various products to treat a range of spinal and sacroiliac conditions, including trauma, degeneration, deformity, and tumor. Xtant Medical Holdings, Inc. markets its products through direct sales, consignment agents, reseller distributors, private label distributors, and technology licensees. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
See More
Previous Close:
$0.5024
Open:
$0.48
24h Volume:
97,468
Relative Volume:
1.07
Market Cap:
$68.22M
Revenue:
$78.46M
Net Income/Loss:
$2.75M
P/E Ratio:
50.86
EPS:
0.01
Net Cash Flow:
$-12.42M
1W Performance:
+3.86%
1M Performance:
+8.21%
6M Performance:
-4.25%
1Y Performance:
-42.22%
1-Day Range:
$0.471
$0.5323
1-Week Range:
$0.3901
$0.54
52-Week Range:
$0.331
$0.918
Xtant Medical Holdings Inc Stock (XTNT) Company Profile
Name
Xtant Medical Holdings Inc
Sector
Industry
Phone
406-388-0480
Address
664 Cruiser Lane, Belgrade, MT
Compare XTNT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XTNT
Xtant Medical Holdings Inc
|
0.5086 | 68.22M | 78.46M | 2.75M | -12.42M | 0.01 |
|
ABT
Abbott Laboratories
|
133.06 | 227.05B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.12 | 152.00B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
377.52 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.32 | 108.50B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
74.92 | 44.68B | 5.54B | 4.18B | 259.90M | 7.00 |
Xtant Medical Holdings Inc Stock (XTNT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-23 | Initiated | BTIG Research | Buy |
| Nov-15-18 | Reiterated | Maxim Group | Buy |
| Feb-14-18 | Reiterated | Maxim Group | Buy |
Xtant Medical Holdings Inc Stock (XTNT) Latest News
Xtant Medical Sets Q1 2025 Earnings Date: MedTech Leader to Discuss Surgical Solutions Growth on May 12 - Stock Titan
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Shares Acquired by Renaissance Technologies LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
How to interpret Xtant Medical Holdings Inc (XTNT)’s stock chart patterns - uspostnews.com
Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance - GuruFocus
Revolutionary Bone Graft Technology: Xtant Medical Unveils Trivium With 20-Year Proven Process - Stock Titan
Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Xtant Medical Holdings (XTNT) and Medtronic (MDT) - The Globe and Mail
Xtant Medical Holdings Inc (AMEX: XTNT) Has Great Upside Potential - stocksregister.com
Xtant Medical announces secondary private sale of existing shares - Medical Buyer
Xtant Medical Ends Investor Agreement After Share Sale - TipRanks
Xtant Medical secures investor support, projects Q1 revenue growth By Investing.com - Investing.com South Africa
Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19% - Ortho Spine News
Xtant Medical Announces Secondary Private Sale Of Existing Shares By Orbimed - marketscreener.com
Major Shakeup: OrbiMed Sells Entire Xtant Medical Stake as Revenue Surges 19% - Stock Titan
Orbimed advisors sells Xtant Medical stock for $30.7 million - Investing.com
Xtant Medical shares change hands in major stock purchase - Investing.com
Xtant Medical shares change hands in major stock purchase By Investing.com - Investing.com India
Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus - ACCESS Newswire
Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Spinal Fusion Device Market Forecast Report and Company Analysis 2025-2033 Featuring Medtronic, Stryker, Zimmer Biomet, Orthofix Medical, NuVasive, Globus Medical, Xtant Medical, and Alphatec – Ortho Spine News - OrthoSpineNews
Spinal Fusion Device Market Forecast Report and Company - GlobeNewswire
Xtant Medical (NYSEAMERICAN:XTNT) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Xtant Medical Faces Risk of Share Distribution by Major Stakeholder, Threatening Stock Stability - MSN
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2024 Earnings Call Transcript - Insider Monkey
Xtant Medical’s Earnings Call: Mixed Outlook with Growth Plans - TipRanks
Earnings call transcript: Xtant Medical Q4 2024 misses EPS, stock drops - Investing.com India
Earnings call transcript: Xtant Medical Q4 2024 misses EPS, stock drops By Investing.com - Investing.com South Africa
Xtant Medical stock target cut to $2 at BTIG, retains buy rating By Investing.com - Investing.com South Africa
Xtant Medical stock target cut to $2 at BTIG, retains buy rating - Investing.com
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Update - Defense World
Xtant Medical Reports Strong 2024 Revenue Growth - TipRanks
Xtant Medical Reports Fourth Quarter and Full Year 2024 Financial Results - Yahoo Finance
Xtant Medical to Issue Fourth Quarter and Year End 2024 Financial Results on March 6, 2025 - Yahoo Finance
Investor Network: Xtant Medical Holdings, Inc. to Host Earnings Call - ACCESS Newswire
Xtant Medical (NYSEAMERICAN:XTNT) Stock Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Drop in Short Interest - MarketBeat
Xtant Medical Holdings Inc (AMEX: XTNT) – An Analysis Is What You Need - Stocks Register
Xtant Medical (NYSEAMERICAN:XTNT) Shares Pass Above 200-Day Moving AverageHere's What Happened - MarketBeat
Spinal Implants Market to Grow by USD 3.55 Billion from 2025-2029, Driven by Rising Spinal Disorder Prevalence, AI's Impact on Market TrendsTechnavio - The Malaysian Reserve
Xtant Medical (NYSEAMERICAN:XTNT) Share Price Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Xtant Medical Holdings Inc Stock (XTNT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.98%
6.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):